New eczema cream could be safer option for kids

NCT ID NCT07162896

Not yet recruiting Disease control Sponsor: Shalamar Institute of Health Sciences Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether crisaborole 2% ointment works better than tacrolimus 0.1% ointment for children aged 2-18 with mild to moderate eczema. 66 children will apply one of the creams twice daily for 28 days. The main goal is to see how many achieve clear or almost clear skin by day 28.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Crisaborole 2% ointment and Tacrolimus 0.1% ointment
What this could lead to: If crisaborole works as well as or better than tacrolimus, it could offer a safer, steroid-free option for managing eczema in children.
What could go wrong: This is a small, early-phase trial with only 66 participants, so results may not apply to all children. Both treatments can cause skin irritation or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS ATOPIC DERMATITIS (AD)

Contacts and locations

Show contact details

Locations

Shalamar Hospital Lahore

Lahore, Punjab Province, 54000, Pakistan

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.